Compare NRG Energy Inc (NRG) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NRG Energy Inc vs TG Therapeutics Inc — how do they compare? NRG Energy Inc trades at $120.66 (market cap $24.83B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: NRG Energy Inc is far larger — about 3.3× TG Therapeutics Inc's market cap, and NRG Energy Inc pays a 1.61% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| NRG | TGTX | |
|---|---|---|
Market Cap | $24.83B | $7.64B |
Sector | Utilities | Health |
52-Week High | $184.03 | $59.06 |
52-Week Low | $117.04 | $26.94 |
Enterprise Value | $48.79B | $7.84B |
Dividend Yield | 1.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NRG Energy trades at $120.37, down 1.23% with a bearish technical signal. Recent Q2 2026 earnings missed estimates at $1.49 EPS versus $1.69 expected, though revenue grew 11% year-over-year. The company is advancing a 1.2 GW Texas data-center power project to capitalize on AI-driven electricity demand, supported by a 69% analyst buy rating and a $207.83 consensus price target. Cash flow from operations was $1.91B in 2025, but net income margin compressed to 2.56%.
Outlook is mixed: growth initiatives in data center power present upside, but execution risks and rising interest costs pressure margins. The stock offers a 1.6% dividend yield, yet high debt-to-asset ratio of 56.42% in 2025 warrants caution. Near-term support lies at $119, with resistance at $122.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
